argenx SEARGX

$877.72-14.54 (-1.63%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$58B

Large-cap

+11763%

2017 — today

10-Year Price

+3535%

2017 — today

52-Week Range

$538.64$929.61

Current $877.72· 87%

Amsterdam-based argenx SE develops innovative immunology therapies. Its lead product, efgartigimod (VYVGART, VYVGART HYTRULO, VYVDURA), addresses conditions including generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The pipeline features candidates like empasiprubart, ARGX-119, and various FcRn-targeting assets. argenx maintains global operations and strategic partnerships with firms including Genmab, AbbVie, Zai Lab, and LEO Pharma to advance its antibody portfolio.

Valuation in context

P/E ratio

35.5

Historically pricey

Historically pricey — last 10 years

P/B ratio

7.9

Historically pricey

Historically pricey — last 10 years

EV / EBITDA

41.2

Below average

Below the 10-year average

Free · No credit card needed

Get alerted when ARGX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.